These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 3954813)

  • 21. Natural killer cells are not required for interferon-mediated prophylaxis against vaccinia or murine cytomegalovirus infections.
    Bukowski JF; McIntyre KW; Yang H; Welsh RM
    J Gen Virol; 1987 Aug; 68 ( Pt 8)():2219-22. PubMed ID: 3039047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surface assembly of poly(I:C) on PEGylated microspheres to shield from adverse interactions with fibroblasts.
    Hafner AM; Burschowsky D; Corthésy B; Textor M; Merkle HP
    J Control Release; 2012 Apr; 159(2):204-14. PubMed ID: 22349184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural killer cell activity against cultured melanoma cells: a dye-reduction technique with studies on augmented activity by interferon subtypes.
    Losinno C; Wines BD; Johns TG; Mackay IR
    Nat Immun; 1992; 11(4):215-24. PubMed ID: 1384830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of residual monomer in PMMA powder and methods of polymerization in the finding of residual monomer in poly(methylmethacrylate) denture base.
    Jerolimov V; Krhen J; Besić J
    Acta Stomatol Croat; 1991; 25(1):17-23. PubMed ID: 1819923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of various cells treated with interferon to the toxic effect of poly(rI).poly(rC) treatment.
    Emeny JM; Morgan MJ
    J Gen Virol; 1979 Apr; 43(1):253-5. PubMed ID: 113495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model.
    Park JS; Kim HS; Park HM; Kim CH; Kim TG
    Vaccine; 2011 Nov; 29(47):8642-8. PubMed ID: 21945963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of interferon alpha/beta in the induction of intestinal pathology in mice.
    Garside P; Felstein MV; Green EA; Mowat AM
    Immunology; 1991 Oct; 74(2):279-83. PubMed ID: 1748474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renewal of natural killer cells in mice having elevated natural killer cell activity.
    Nassiry L; Miller SC
    Nat Immun Cell Growth Regul; 1987; 6(5):250-9. PubMed ID: 3444438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killing in estrogen-treated mice responds poorly to poly I.C despite normal stimulation of circulating interferon.
    Seaman WE; Merigan TC; Talal N
    J Immunol; 1979 Dec; 123(6):2903-5. PubMed ID: 227961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic metabolic alterations associated with repeated injections of a modified polyriboinosinic-polyribocytidylic acid complex.
    Powanda MC; Sammons ML; Stephen EL
    Antimicrob Agents Chemother; 1977 Nov; 12(5):602-5. PubMed ID: 921256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anti-tetanus immune response of neonatal mice is augmented by retinoic acid combined with polyriboinosinic:polyribocytidylic acid.
    Ma Y; Ross AC
    Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13556-61. PubMed ID: 16157890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditioned augmentation of natural killer cell activity. Independence from nociceptive effects and dependence on interferon-beta.
    Solvason HB; Ghanta VK; Hiramoto RN
    J Immunol; 1988 Jan; 140(2):661-5. PubMed ID: 2826599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new procedure to immobilize polyriboinosinic-polyribocytidylic acid (poly I:C) on the surface of polymethylmethacrylate and the use of poly I:C in clinical hemoperfusion.
    Hydén H; Holmberg K
    Arzneimittelforschung; 1986; 36(1):120-3. PubMed ID: 3954813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methods of immobilization of proteins to polymethylmethacrylate.
    Holmberg K; Hydén H
    Prep Biochem; 1985; 15(5):309-19. PubMed ID: 3938844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.
    Hawkins MJ; Levin M; Borden EC
    J Biol Response Mod; 1985 Dec; 4(6):664-8. PubMed ID: 2418164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracorporeal interferon therapy in malignant melanoma. Significant economies of interferon in an extracorporeal chamber.
    Langvad E; Hydén H; Petersen JK; Jordal R; Olsen G
    Arzneimittelforschung; 1980; 30(8):1245-6. PubMed ID: 6159905
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.